GPR62 | G protein-coupled receptor 62 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPRC5A | G protein-coupled receptor, family C, group 5, member A | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPRC5B | G protein-coupled receptor, family C, group 5, member B | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GRM1 | Glutamate receptor, metabotropic 1 | Disease related genes G-protein coupled receptors Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
HAS3 | Hyaluronan synthase 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
HM13 | Histocompatibility (minor) 13 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
HRH1 | Histamine receptor H1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HTR7 | 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
HTT | Huntingtin | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
ITPR1 | Inositol 1,4,5-trisphosphate receptor, type 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ITPR3 | Inositol 1,4,5-trisphosphate receptor, type 3 | Plasma proteins Predicted membrane proteins
| | | | | Mixed |
KCNG1 | Potassium voltage-gated channel, subfamily G, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
LGR6 | Leucine-rich repeat containing G protein-coupled receptor 6 | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MBTPS2 | Membrane-bound transcription factor peptidase, site 2 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
MFSD2A | Major facilitator superfamily domain containing 2A | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MPDU1 | Mannose-P-dolichol utilization defect 1 | Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
MT-CO3 | Mitochondrially encoded cytochrome c oxidase III | Disease related genes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
NMBR | Neuromedin B receptor | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
NOX1 | NADPH oxidase 1 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
NPFFR2 | Neuropeptide FF receptor 2 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
OR7C1 | Olfactory receptor, family 7, subfamily C, member 1 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY10 | Purinergic receptor P2Y, G-protein coupled, 10 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
P2RY13 | Purinergic receptor P2Y, G-protein coupled, 13 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PARL | Presenilin associated, rhomboid-like | Enzymes Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |
PHTF1 | Putative homeodomain transcription factor 1 | Plasma proteins Predicted membrane proteins Transcription factors
| | | | | Expressed in all |
PSEN1 | Presenilin 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
PSEN2 | Presenilin 2 (Alzheimer disease 4) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
PTAFR | Platelet-activating factor receptor | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
PTCHD3 | Patched domain containing 3 | Predicted membrane proteins
| | | | | Tissue enriched |
RHBDL1 | Rhomboid, veinlet-like 1 (Drosophila) | Enzymes Predicted membrane proteins
| | | | | Mixed |
SLC13A3 | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC15A3 | Solute carrier family 15 (oligopeptide transporter), member 3 | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
SLC16A1 | Solute carrier family 16 (monocarboxylate transporter), member 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC16A3 | Solute carrier family 16 (monocarboxylate transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC17A4 | Solute carrier family 17, member 4 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC1A6 | Solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC22A16 | Solute carrier family 22 (organic cation/carnitine transporter), member 16 | Predicted membrane proteins
| | | | | Group enriched |
SLC30A7 | Solute carrier family 30 (zinc transporter), member 7 | Predicted membrane proteins Transporters
| | | | | Mixed |
SLC35A2 | Solute carrier family 35 (UDP-galactose transporter), member A2 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC38A7 | Solute carrier family 38, member 7 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC50A1 | Solute carrier family 50 (sugar efflux transporter), member 1 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC51A | Solute carrier family 51, alpha subunit | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
SLCO1B3 | Solute carrier organic anion transporter family, member 1B3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLCO6A1 | Solute carrier organic anion transporter family, member 6A1 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |